Occupation: Research House
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants.
Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries.
Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Run by a team of highly experienced professionals, our aim is to provide the research of choice for companies, investment banks and institutional investors. We provide independent reports, forecasts and valuations on each company we cover. We help clients gain access to investors, and facilitate feedback from the investment community on companies, their management and strategies. Our research strives to be objective, insightful, financially rigorous, readable and timely.
Web Address: http://www.edisongroup.com
280 High Holborn
Tel: Tel: +44 (0)20 3077 5700
TiGenix is developing clinical studies in rheumatoid arthritis and sepsis for Cx611, its expanded adipose stem cell (eASC) intravenous therapy. The first stage planned is a pilot volunteer sepsis study starting in early 2015 with data possible in Q315. The Phase II RA study from Q315 will focus on achieving minimal disease activity in patients who fail to respond to initial treatment with standard agents.…
MagForce’s strategy to increase uptake of its NanoTherm therapy is on track and progress has been made in both Europe and the US in line with expectations. In Europe the installed base of NanoActivators has increased and the first patient was enrolled into the post-marketing glioblastoma (GBM) study. In the US, a positive pre-submission meeting was held with the FDA, confirming that NanoTherm will be…
Utilico Emerging Markets Limited (UEM) is a closed-end investment company investing in utilities, infrastructure and related companies in emerging markets. Its specific sector focus differentiates it from other emerging market funds, as does its dividend yield of over 3%, reflecting its focus on cash-generative businesses. NAV total return performance has exceeded peer group averages over one, three and five years and it has the lowest…
Evonik’s consolidation of its partnership with Borussia Dortmund is a strong endorsement of management’s development of the BVB brand. Long-term extension of its leading sponsorship agreement enhances Dortmund’s revenue security while c €26m proceeds from Evonik’s new 9% stake will address a current spike in net player spend. The prospect of further partnerships, secured by capital increases, is welcome in terms of cash and the…